Literature DB >> 22579861

New technologies for new influenza vaccines.

Alan Shaw1.   

Abstract

The currently available influenza vaccines were developed in the 1930s through the 1960s using technologies that were state-of-the art for the times. Decades of advancement in virology and immunology have provided the tools for making better vaccines against influenza. We now have the means to make vaccines that address some of the shortcomings of the original products, in particular performance in the elderly.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Mesh：

Substances：

Year:  2012        PMID： 22579861     DOI： 10.1016/j.vaccine.2012.04.095

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.

Authors:  Rekha Dhanwani; Yanqin Zhou; Qinfeng Huang; Vikram Verma; Mythili Dileepan; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

3.  Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013.

Authors:  Marc P Girard; John S Tam; Yuri Pervikov; Jacqueline M Katz
Journal:  Vaccine       Date:  2013-06-27       Impact factor: 3.641

4.  Technology Resource, Distribution, and Development Characteristics of Global Influenza Virus Vaccine: A Patent Bibliometric Analysis.

Authors:  Ning Chen; Yun Liu; Yijie Cheng; Long Liu; Zhe Yan; Lixin Tao; Xiuhua Guo; Yanxia Luo; Aoshuang Yan
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

5.  Early vaccine availability represents an important public health advance for the control of pandemic influenza.

Authors:  Amy L Greer
Journal:  BMC Res Notes       Date:  2015-05-08

6.  Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.

Authors:  David A G Skibinski; Brendon J Hanson; Yufang Lin; Veronika von Messling; Andrea Jegerlehner; Jason Boon Sern Tee; De Hoe Chye; Steven K K Wong; Amanda A P Ng; Hui Yin Lee; Bijin Au; Bernett T K Lee; Lucia Santoso; Michael Poidinger; Anna-Marie Fairhurst; Alex Matter; Martin F Bachmann; Philippe Saudan; John E Connolly
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

7.  Hydrophobin fusion of an influenza virus hemagglutinin allows high transient expression in Nicotiana benthamiana, easy purification and immune response with neutralizing activity.

Authors:  Nicolas Jacquet; Catherine Navarre; Daniel Desmecht; Marc Boutry
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 8.  Current and emerging cell culture manufacturing technologies for influenza vaccines.

Authors:  Ernest Milián; Amine A Kamen
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

9.  Requirements of New Vaccines against Novel Influenza Viruses.

Authors:  Osamu Kobayashi
Journal:  Trop Med Health       Date:  2014-06

Review 10.  Influenza vaccines: unmet needs and recent developments.

Authors:  Ji Yun Noh; Woo Joo Kim
Journal:  Infect Chemother       Date:  2013-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.